Fennec Pharmaceuticals Reports Impressive Q3 Results for 2024
~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~
~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~
~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer Appointments ~
~ Company Has Approximately $40 Million in Cash, Cash Equivalents, and Investment Securities Expected to Fund Operations Into at Least 2026 ~
~ Management to Host Conference Call Today at 8:30 a.m. ET ~
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, recently disclosed its financial performance for the third quarter and shared key updates on its business activities.
Jeff Hackman, the newly appointed CEO, expressed enthusiasm about the accomplishments made since taking the helm in August. He noted that cementing relationships with payors and increasing market penetration among the AYA community are crucial steps towards positioning Fennec for sustainable growth. Hackman emphasized that the investments made in educational initiatives reflect the solid foundation upon which the company is building with PEDMARK, and he expects to see accelerated growth and enhanced value across critical market segments.
Recent Developments and Highlights
Key Executive Appointments: Fennec has onboarded industry veterans Pierre S. Sayad, PhD, M.S., as Chief Medical Officer, Terry Evans as Chief Commercial Officer, and Christiana Cioffi, MBA, as Chief Strategy Officer. Their collective expertise in clinical and commercial strategy is expected to facilitate the execution of the company’s integrated commercial approach for PEDMARK.
Reimbursement Milestone: The company has reported over 90% reimbursement for PEDMARK among the AYA demographic during Q3. Insights from market analysis indicate a significant opportunity, with an annual estimate of 10,000 patients treated with cisplatin, which carries a risk of hearing impairment due to ototoxicity.
European Launch of PEDMARQSI: In Europe, Fennec is set to launch PEDMARQSI, following an exclusive licensing deal with Norgine, with expected revenue generation in 2025.
Clinical Trials Update: In Japan, the contractor-initiated clinical trial (STS-J01) intended to evaluate the efficacy and safety of PEDMARK is fully enrolled as of October 2024. The results are anticipated to support registration for PEDMARK in Japan, targeting patients with solid tumors.
Active Participation in Scientific Conferences: During the third quarter, Fennec engaged in various scientific events, enhancing visibility and outreach within the oncology community.
Q3 2024 Financial Overview
Net Product Sales: The company reported net product sales totaling $7.0 million for the three months concluded on September 30, 2024, which is an increase from $6.5 million during the equivalent period in 2023.
Cash Reserves: Cash and cash equivalents on record were $40.3 million. The company noted that cash levels decreased by $2.7 million from the previous quarter, primarily attributed to operational expenses associated with product promotion and overhead costs. Nonetheless, they anticipate that available funds will sustain operations well into 2026.
Research and Development Expenditures: The company's selling and marketing expenses saw an uptick to $4.6 million from $3.4 million year over year. This increase is reflective of an expanded focus on the AYA oncology demographic.
General and Administrative Costs: General and administrative expenses reached $6.1 million compared to $3.8 million for the same quarter in 2023, partly due to non-cash equity compensations and other costs tied to previous executive transitions.
Net Loss Overview: The net loss for the quarter came in at $5.7 million, translating to a basic and diluted loss of $0.21 per share, compared with a loss of $1.9 million, or $0.07 per share in Q3 2023.
Upcoming Conference Call
Date: Thursday, November 7, 2024
Time: 8:30 a.m. ET
To join the conference call, participants can dial 888-596-4144 or 646-968-2525 internationally, referencing access ID: 6896851.
About Cisplatin-Induced Ototoxicity
Cisplatin is a cornerstone chemotherapy agent for treating several pediatric cancers but presents a risk of ototoxicity, leading to permanent hearing loss. This is particularly damaging when it affects young patients, as it can severely hinder their developmental, educational, and social outcomes.
PEDMARK and its Role
PEDMARK is recognized as the first FDA-approved therapy aimed at mitigating the risk of ototoxicity from cisplatin in pediatric patients. With a proven safety and efficacy profile, it poses a significant public health advancement in the treatment of children undergoing platinum-based chemotherapy.
Blue Sky Strategies
In conclusion, Fennec is committed to driving the adoption of PEDMARK and enhancing its market presence, with a clear roadmap and experienced leadership to navigate the complexities of the pediatric oncology landscape. In this vein, the company also pays close attention to regulatory developments that may affect its products.
Frequently Asked Questions
What were the net product sales for Fennec Pharmaceuticals in Q3 2024?
Fennec Pharmaceuticals achieved net product sales of $7.0 million for the third quarter of 2024.
What strategic investments has Fennec made recently?
The company has focused on driving awareness of ototoxicity and increasing reimbursement for PEDMARK among the AYA community.
Who are the new executive appointments at Fennec Pharmaceuticals?
Pierre S. Sayad, Terry Evans, and Christiana Cioffi have been appointed as Chief Medical Officer, Chief Commercial Officer, and Chief Strategy Officer, respectively.
What is the anticipated cash runway for Fennec Pharmaceuticals?
The company expects its cash, cash equivalents, and investment securities to sustain operations well into at least 2026.
What is PEDMARK used for?
PEDMARK is indicated to reduce the risk of ototoxicity in pediatric patients undergoing treatment with cisplatin.
